<DOC>
	<DOCNO>NCT01025297</DOCNO>
	<brief_summary>This study design evaluate safety biological active dose new experimental drug , IL-7 , combination standard bi-therapy patient Hepatitis C chronic infection identify non responder standard bi-therapy alone .</brief_summary>
	<brief_title>Dose Escalation Study Interleukin-7 ( IL-7 ) Bitherapy HCV Genotype 1 4 Patients Resistant Bitherapy Alone</brief_title>
	<detailed_description>This Phase I/IIa inter-patient dose-escalation study assess weekly dos Interleukin-7 ( CYT107 ) adult patient infect virus genotype 1 4 Hepatitis C resistant standard treatment Peg-Interferon Ribavirin ( bitherapy ) . The dose escalation aim establish safety biologically active dos CYT107 add combination therapy pegylated interferon-alpha ribavirin . At dose level , study patient receive one subcutaneous administration CYT107 per week total 4 . Groups 6 patient enter dose level CYT107 . Three dose level plan . Eligible patient initially receive bi-therapy 6-10 week . Thereafter , CYT107 add cycle four weekly injection define dose level standard bi-therapy continue 9 week CYT107 treatment discontinuation . The patient follow regular basis reach 48 week CYT107 treatment . The duration study approximatively 60 week 20-25 week bi-therapy . Participants 1 overnight hospitalization 15 clinic visit period 60 week . During visit follow may do : - medical history , physical examination , blood test - electrocardiogram ( ECG ) - chest X-Ray - liver/spleen image - urine test</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Genotype 1 4 infected patient Age &gt; 18 year Absence viral response previous treatment pegylated interferonalpha plus ribavirin define : Absence early viral response ( EVR ) detectable HCV decrease HCV RNA load &lt; 2 log , measure quantitative PCR test 12 week treatment , compare baseline level measure similar technique ; Absence end treatment response define detectable HCV RNA end treatment ( 24 week 48 week ) Metavir ≤ F3 assess biopsy last 12 month fibroscan Fibroscan® result &lt; 10 kPa last 6 month ( biopsy avoid ) Active infection HBV ( positive HBs Ag positive anti HBc antibodies detectable HBV DNA viral load ) . Infection HIV1 /or HIV2 Apart HCV infection , presence active infection require specific treatment hospitalization Other liver disease ( notably alcoholic , metabolic immunological origin ) Body mass index ( BMI ) &gt; 30kg/m2 Relapse previous response pegylated IFN alpha ribavirin therapy Any history malignancy apart curatively treat basal cell carcinoma situ cervical carcinoma History clinical autoimmune disease active autoimmune disease History severe asthma , presently chronic medication Significant cardiac pulmonary disease Prior solid organ hematopoietic cell transplantation Dialyzed patient Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>interleukin-7</keyword>
	<keyword>immune-based therapy</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>chronic hepatitis</keyword>
	<keyword>resistance Peg-interferon ribavirin bi-therapy</keyword>
	<keyword>immune specific response HCV</keyword>
	<keyword>phase 1/2a</keyword>
	<keyword>viral disease</keyword>
	<keyword>liver disease</keyword>
</DOC>